Steffen Wedel

Three-year Safety of Radium-223 Dichloride in Patients with Castration-resistant Prostate Cancer and Symptomatic Bone Metastases from Phase 3 Randomized Alpharadin in Symptomatic Prostate Cancer Trial

Christopher Parker, Robert E. Coleman, Oliver Sartor, Nicholas J. Vogelzang et autres

gb, us, no, pl, se, sk, de, br (code pays fourni par la source)

Self-adjuvanted mRNA vaccination in advanced prostate cancer patients: a first-in-man phase I/IIa study

Hubert Kübler, Birgit Scheel, Ulrike Gnad-Vogt, Kurt Miller et autres

de, it (code pays fourni par la source)

A Randomised Phase 2 Study Combining LY2181308 Sodium (Survivin Antisense Oligonucleotide) with First-line Docetaxel/Prednisone in Patients with Castration-resistant Prostate Cancer

Paweł Wiechno, Bradley G. Somer, Begoña Mellado, Piotr Chłosta et autres

pl, es, de, gb, us (code pays fourni par la source)

Randomized phase II study with window-design to evaluate anti-tumor activity of the survivin antisense oligonucleotide (ASO) ly2181308 in combination with docetaxel for first-line treatment of castrate-resistant prostate cancer (CRPC).

Paweł Wiechno, Piotr Chłosta, Joanna Pikiel, Bradley G. Somer et autres

pl, es, de, gb, us (code pays fourni par la source)

Chemokines involved in tumor promotion and dissemination in patients with renal cell cancer

Igor Tsaur, Anika Noack, Ana Maria Waaga-Gasser, Jasmina Makarević et autres

de (code pays fourni par la source)

Low dosed interferon alpha augments the anti‐tumor potential of histone deacetylase inhibition on prostate cancer cell growth and invasion

Lukasz Hudak, Patrick Tezeeh, Steffen Wedel, Jasmina Makarević et autres

de (code pays fourni par la source)

784 OVERCOMING RAD001 TRIGGERED RESISTANCE IN PROSTATE CANCER CDK1-CYCLIN B COMPLEX

Igor Tsaur, Jasmina Makarević, Michael Reiter, M. Kurosch et autres

783 THE EFFECTS OF HDAC-INHIBITION ON TUMOR GROWTH AND INTEGRIN DRIVEN INVASION PROCESSES ARE AUGMENTED BY LOW DOSED INTERFERON ALPHA IN PROSTATE CANCER MODELS IN VITRO AND IN VIVO

Steffen Wedel, Lukasz Hudak, Igor Tsaur, Jasmina Makarević et autres

130 Overall survival benefit and impact on skeletal-related events for radium-223 chloride (Alpharadin) in the treatment of castration-resistant prostate cancer (CRPC) patients with bone metastases: A phase III randomized trial (ALSYMPCA)

Chris Parker, Daniel Heinrich, Svein Inge Helle, Joe M. O’Sullivan et autres

238 The effects of HDAC-inhibition on tumor growth and integrin driven invasion processes are augmented by low dosed interferon alpha in prostate cancer models in vitro and in vivo

Steffen Wedel, L. Hudak, Igor Tsaur, Jasmina Makarević et autres

Molecular targeting of prostate cancer cells by a triple drug combination down-regulates integrin driven adhesion processes, delays cell cycle progression and interferes with the cdk-cyclin axis

Steffen Wedel, Lukasz Hudak, Jens‐Michael Seibel, Jasmina Makarević et autres

de (code pays fourni par la source)

416 IMPACT OF COMBINED HDAC AND MTOR INHIBITION ON THE INVASIVE POTENTIAL OF PROSTATE CANCER CELLS

Steffen Wedel, L. Hudak, Jasmina Makarević, Jens‐Michael Seibel et autres